Report banner
Home
Industries
Healthcare
Live Attenuated Vaccines Market
Updated On

Jan 17 2025

Total Pages

190

Market
Insights

7,500+

Reports delivered globally, covering a wide range of industries and sectors.

2,350+

Clients who trust our expertise and rely on our insights for business decisions.

1,050+

Managed Reports, ensuring seamless updates and premium service.

100%

Satisfied Customers, committed to delivering exceptional value and quality.

Live Attenuated Vaccines Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Live Attenuated Vaccines Market by Vaccine Type (Bacterial vaccine, Viral vaccine), by Development (Tissue culture, Embryonated eggs, Live animals), by Mode of Administration (Oral, Injectable, Intranasal), by Age Group (Pediatric, Adult), by Indication (Tuberculosis, Measles, Rotavirus, Yellow fever, Oral polio, Influenza, Other indications), by End-use (Hospitals, Specialty clinics, Other end-users), by North America (U.S., Canada), by Europe (Germany, UK, France, Italy, Spain, Rest of Europe), by Asia Pacific (Japan, China, India, Australia, Rest of Asia Pacific), by Latin America (Brazil, Mexico, Rest of Latin America), by Middle East and Africa (South Africa, Saudi Arabia, Rest of Middle East and Africa) Forecast 2025-2033

Main Logo

Live Attenuated Vaccines Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities

Key Insights

The size of the Live Attenuated Vaccines market was valued at USD XXX Billion in 2023 and is projected to reach USD XXX Billion by 2032, with an expected CAGR of 10.4% during the forecast period.Live attenuated vaccines are biological preparations that consist of a weakened form of a living microorganism, which can be a virus or bacteria. Attenuation can occur through genetic manipulation or extended incubation in the laboratory. Though the microorganism in the vaccine is weak, it is still replicative within the body of the recipient and causes an immune response very similar to that seen with a natural infection. This intense immunity is often associated with long-term immunity. The live attenuated vaccines are highly protective for most of the infectious diseases including measles, mumps, rubella, polio, and chickenpox.

Live Attenuated Vaccines Market Research Report - Market Size, Growth & Forecast

Live Attenuated Vaccines Market Concentration & Characteristics

Concentration Areas

The Live Attenuated Vaccines market exhibits a moderate level of concentration, with a few major players holding a significant market share. These key players possess strong brand recognition, well-established distribution networks, and extensive research and development capabilities.

Innovation

The market is highly innovation-driven, with continuous advancements in vaccine technologies. Companies are actively involved in developing novel live attenuated vaccines with improved efficacy, safety, and stability profiles.

Regulations

Stringent regulatory guidelines govern the development, manufacturing, and distribution of live attenuated vaccines to ensure their safety and effectiveness. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in shaping the market landscape.

Product Substitutes

While live attenuated vaccines are effective in preventing infectious diseases, they have certain limitations. The availability of alternative vaccines, such as inactivated vaccines, recombinant vaccines, and mRNA vaccines, may limit the market growth to some extent.

End User Concentration

The primary end users of live attenuated vaccines include hospitals (public and private), specialty clinics, and other healthcare facilities. Hospitals account for a significant portion of the market due to their high volume of patient vaccinations.

Level of M&A

The Live Attenuated Vaccines market has witnessed a steady level of mergers and acquisitions, as companies seek to expand their portfolios, consolidate market share, and gain access to new technologies.

Live Attenuated Vaccines Market Trends

Rising Prevalence of Infectious Diseases

The increasing prevalence of infectious diseases worldwide is a major driver of the Live Attenuated Vaccines market. The emergence of new strains and the spread of existing ones highlight the need for effective vaccines to protect populations.

Technological Advancements

Advancements in vaccine technology, such as the development of recombinant live attenuated vaccines, have led to improved vaccine efficacy, safety, and stability. These advancements are expected to further drive market growth.

Increasing Government Funding

Governments worldwide recognize the importance of vaccination in preventing outbreaks and improving public health. Increased government funding for vaccine research and development, as well as immunization programs, is a key market driver.

Expansion into Emerging Markets

The growing healthcare infrastructure and rising demand for vaccines in developing countries present significant growth opportunities for the Live Attenuated Vaccines market.

Live Attenuated Vaccines Market Growth

Key Region or Country & Segment to Dominate the Market

Region/Country

North America and Europe currently dominate the Live Attenuated Vaccines market, due to their advanced healthcare systems, high vaccination rates, and stringent regulatory frameworks.

Segment

Viral vaccines, such as measles, mumps, and rubella (MMR) vaccines, account for a significant share of the market as they are essential for childhood immunization programs.

Indication

Tuberculosis, measles, rotavirus, yellow fever, oral polio, and influenza are among the most common indications for live attenuated vaccines.

Live Attenuated Vaccines Market Product Insights Report Coverage & Deliverables

The report provides a comprehensive overview of the Live Attenuated Vaccines market, including:

  • Market size and growth projections
  • Product insights and market trends
  • Competitive landscape and company profiles
  • Regional analysis and key insights
  • Industry news and developments

Live Attenuated Vaccines Market Analysis

Market Size and Growth

The global Live Attenuated Vaccines market is estimated to reach 24.5 Billion by 2028, registering a CAGR of 10.4%. This growth is driven by factors such as the rising prevalence of infectious diseases, government initiatives, and technological advancements.

Market Share

Abbott, GlaxoSmithKline, and Sanofi are the leading players in the Live Attenuated Vaccines market, collectively holding a significant market share.

Driving Forces: What's Propelling the Live Attenuated Vaccines Market

  • Rising prevalence of infectious diseases
  • Government initiatives and funding
  • Technological advancements
  • Increasing demand in emerging markets

Challenges and Restraints in Live Attenuated Vaccines Market

  • Stringent regulatory requirements
  • Product safety concerns
  • Competition from alternative vaccines
  • Limited production capacity

Emerging Trends in Live Attenuated Vaccines Market

  • Development of recombinant live attenuated vaccines
  • Personalized vaccine approaches
  • Advancements in vaccine delivery systems

Live Attenuated Vaccines Industry News

November 2023

  • Valneva SE obtained U.S. FDA approval for IXCHIQ, a single-dose live-attenuated vaccine for preventing chikungunya virus disease in adults at higher risk.

May 2023

  • Biofabri, a Zendal subsidiary, and IAVI signed an agreement for the development of MTBVAC, a tuberculosis vaccine candidate.

Leading Players in the Live Attenuated Vaccines Market Keyword

  • Abbott
  • Bharat Biotech International Limited
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc.
  • Haffkine Biopharmaceutical Corporation Limited
  • HBI
  • Merck & Co.
  • Novartis Pharmaceuticals Corporation
  • Sanofi
  • Serum Institute of India Ltd.
  • Valneva SE
  • Zydus Group

Live Attenuated Vaccines Market Segmentation

1. Vaccine Type

  • 1.1. Bacterial vaccine
  • 1.2. Viral vaccine

2. Development

  • 2.1. Tissue culture
  • 2.2. Embryonated eggs
  • 2.3. Live animals

3. Mode of Administration

  • 3.1. Oral
  • 3.2. Injectable
  • 3.3. Intranasal

4. Age Group

  • 4.1. Pediatric
  • 4.2. Adult

5. Indication

  • 5.1. Tuberculosis
  • 5.2. Measles
  • 5.3. Rotavirus
  • 5.4. Yellow fever
  • 5.5. Oral polio
  • 5.6. Influenza
  • 5.7. Other indications

6. End-use

  • 6.1. Hospitals
    • 6.1.1. Public
    • 6.1.2. Private
  • 6.2. Specialty clinics
  • 6.3. Other end-users

Live Attenuated Vaccines Market Segmentation By Geography

1. North America

  • 1.1. U.S.
  • 1.2. Canada

2. Europe

  • 2.1. Germany
  • 2.2. UK
  • 2.3. France
  • 2.4. Italy
  • 2.5. Spain
  • 2.6. Rest of Europe

3. Asia Pacific

  • 3.1. Japan
  • 3.2. China
  • 3.3. India
  • 3.4. Australia
  • 3.5. Rest of Asia Pacific

4. Latin America

  • 4.1. Brazil
  • 4.2. Mexico
  • 4.3. Rest of Latin America

5. Middle East and Africa

  • 5.1. South Africa
  • 5.2. Saudi Arabia
  • 5.3. Rest of Middle East and Africa

Live Attenuated Vaccines Market Regional Share

Live Attenuated Vaccines Market REPORT HIGHLIGHTS

AspectsDetails
Study Period 2019-2033
Base Year 2024
Estimated Year 2025
Forecast Period2025-2033
Historical Period2019-2024
Growth RateCAGR of 10.4% from 2019-2033
Segmentation
    • By Vaccine Type
      • Bacterial vaccine
      • Viral vaccine
    • By Development
      • Tissue culture
      • Embryonated eggs
      • Live animals
    • By Mode of Administration
      • Oral
      • Injectable
      • Intranasal
    • By Age Group
      • Pediatric
      • Adult
    • By Indication
      • Tuberculosis
      • Measles
      • Rotavirus
      • Yellow fever
      • Oral polio
      • Influenza
      • Other indications
    • By End-use
      • Hospitals
        • Public
        • Private
      • Specialty clinics
      • Other end-users
  • By Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • South Africa
      • Saudi Arabia
      • Rest of Middle East and Africa
Table Of Content
  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Introduction
  3. 3. Market Dynamics
    • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1 Growing prevalence of infectious diseases
        • 3.2.2 Expanding vaccination programs
        • 3.2.3 Growing advancements in vaccine development
        • 3.2.4 Robust government support & funding for vaccine development
      • 3.3. Market Restrains
        • 3.3.1 High cost associated with vaccine development
        • 3.3.2 Stringent regulations for the approval
      • 3.4. Market Trends
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  5. 5. Global Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 5.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 5.1.1. Bacterial vaccine
      • 5.1.2. Viral vaccine
    • 5.2. Market Analysis, Insights and Forecast - by Development
      • 5.2.1. Tissue culture
      • 5.2.2. Embryonated eggs
      • 5.2.3. Live animals
    • 5.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 5.3.1. Oral
      • 5.3.2. Injectable
      • 5.3.3. Intranasal
    • 5.4. Market Analysis, Insights and Forecast - by Age Group
      • 5.4.1. Pediatric
      • 5.4.2. Adult
    • 5.5. Market Analysis, Insights and Forecast - by Indication
      • 5.5.1. Tuberculosis
      • 5.5.2. Measles
      • 5.5.3. Rotavirus
      • 5.5.4. Yellow fever
      • 5.5.5. Oral polio
      • 5.5.6. Influenza
      • 5.5.7. Other indications
    • 5.6. Market Analysis, Insights and Forecast - by End-use
      • 5.6.1. Hospitals
        • 5.6.1.1. Public
        • 5.6.1.2. Private
      • 5.6.2. Specialty clinics
      • 5.6.3. Other end-users
    • 5.7. Market Analysis, Insights and Forecast - by Region
      • 5.7.1. North America
      • 5.7.2. Europe
      • 5.7.3. Asia Pacific
      • 5.7.4. Latin America
      • 5.7.5. Middle East and Africa
  6. 6. North America Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 6.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 6.1.1. Bacterial vaccine
      • 6.1.2. Viral vaccine
    • 6.2. Market Analysis, Insights and Forecast - by Development
      • 6.2.1. Tissue culture
      • 6.2.2. Embryonated eggs
      • 6.2.3. Live animals
    • 6.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 6.3.1. Oral
      • 6.3.2. Injectable
      • 6.3.3. Intranasal
    • 6.4. Market Analysis, Insights and Forecast - by Age Group
      • 6.4.1. Pediatric
      • 6.4.2. Adult
    • 6.5. Market Analysis, Insights and Forecast - by Indication
      • 6.5.1. Tuberculosis
      • 6.5.2. Measles
      • 6.5.3. Rotavirus
      • 6.5.4. Yellow fever
      • 6.5.5. Oral polio
      • 6.5.6. Influenza
      • 6.5.7. Other indications
    • 6.6. Market Analysis, Insights and Forecast - by End-use
      • 6.6.1. Hospitals
        • 6.6.1.1. Public
        • 6.6.1.2. Private
      • 6.6.2. Specialty clinics
      • 6.6.3. Other end-users
  7. 7. Europe Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 7.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 7.1.1. Bacterial vaccine
      • 7.1.2. Viral vaccine
    • 7.2. Market Analysis, Insights and Forecast - by Development
      • 7.2.1. Tissue culture
      • 7.2.2. Embryonated eggs
      • 7.2.3. Live animals
    • 7.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 7.3.1. Oral
      • 7.3.2. Injectable
      • 7.3.3. Intranasal
    • 7.4. Market Analysis, Insights and Forecast - by Age Group
      • 7.4.1. Pediatric
      • 7.4.2. Adult
    • 7.5. Market Analysis, Insights and Forecast - by Indication
      • 7.5.1. Tuberculosis
      • 7.5.2. Measles
      • 7.5.3. Rotavirus
      • 7.5.4. Yellow fever
      • 7.5.5. Oral polio
      • 7.5.6. Influenza
      • 7.5.7. Other indications
    • 7.6. Market Analysis, Insights and Forecast - by End-use
      • 7.6.1. Hospitals
        • 7.6.1.1. Public
        • 7.6.1.2. Private
      • 7.6.2. Specialty clinics
      • 7.6.3. Other end-users
  8. 8. Asia Pacific Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 8.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 8.1.1. Bacterial vaccine
      • 8.1.2. Viral vaccine
    • 8.2. Market Analysis, Insights and Forecast - by Development
      • 8.2.1. Tissue culture
      • 8.2.2. Embryonated eggs
      • 8.2.3. Live animals
    • 8.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 8.3.1. Oral
      • 8.3.2. Injectable
      • 8.3.3. Intranasal
    • 8.4. Market Analysis, Insights and Forecast - by Age Group
      • 8.4.1. Pediatric
      • 8.4.2. Adult
    • 8.5. Market Analysis, Insights and Forecast - by Indication
      • 8.5.1. Tuberculosis
      • 8.5.2. Measles
      • 8.5.3. Rotavirus
      • 8.5.4. Yellow fever
      • 8.5.5. Oral polio
      • 8.5.6. Influenza
      • 8.5.7. Other indications
    • 8.6. Market Analysis, Insights and Forecast - by End-use
      • 8.6.1. Hospitals
        • 8.6.1.1. Public
        • 8.6.1.2. Private
      • 8.6.2. Specialty clinics
      • 8.6.3. Other end-users
  9. 9. Latin America Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 9.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 9.1.1. Bacterial vaccine
      • 9.1.2. Viral vaccine
    • 9.2. Market Analysis, Insights and Forecast - by Development
      • 9.2.1. Tissue culture
      • 9.2.2. Embryonated eggs
      • 9.2.3. Live animals
    • 9.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 9.3.1. Oral
      • 9.3.2. Injectable
      • 9.3.3. Intranasal
    • 9.4. Market Analysis, Insights and Forecast - by Age Group
      • 9.4.1. Pediatric
      • 9.4.2. Adult
    • 9.5. Market Analysis, Insights and Forecast - by Indication
      • 9.5.1. Tuberculosis
      • 9.5.2. Measles
      • 9.5.3. Rotavirus
      • 9.5.4. Yellow fever
      • 9.5.5. Oral polio
      • 9.5.6. Influenza
      • 9.5.7. Other indications
    • 9.6. Market Analysis, Insights and Forecast - by End-use
      • 9.6.1. Hospitals
        • 9.6.1.1. Public
        • 9.6.1.2. Private
      • 9.6.2. Specialty clinics
      • 9.6.3. Other end-users
  10. 10. Middle East and Africa Live Attenuated Vaccines Market Analysis, Insights and Forecast, 2019-2031
    • 10.1. Market Analysis, Insights and Forecast - by Vaccine Type
      • 10.1.1. Bacterial vaccine
      • 10.1.2. Viral vaccine
    • 10.2. Market Analysis, Insights and Forecast - by Development
      • 10.2.1. Tissue culture
      • 10.2.2. Embryonated eggs
      • 10.2.3. Live animals
    • 10.3. Market Analysis, Insights and Forecast - by Mode of Administration
      • 10.3.1. Oral
      • 10.3.2. Injectable
      • 10.3.3. Intranasal
    • 10.4. Market Analysis, Insights and Forecast - by Age Group
      • 10.4.1. Pediatric
      • 10.4.2. Adult
    • 10.5. Market Analysis, Insights and Forecast - by Indication
      • 10.5.1. Tuberculosis
      • 10.5.2. Measles
      • 10.5.3. Rotavirus
      • 10.5.4. Yellow fever
      • 10.5.5. Oral polio
      • 10.5.6. Influenza
      • 10.5.7. Other indications
    • 10.6. Market Analysis, Insights and Forecast - by End-use
      • 10.6.1. Hospitals
        • 10.6.1.1. Public
        • 10.6.1.2. Private
      • 10.6.2. Specialty clinics
      • 10.6.3. Other end-users
  11. 11. Competitive Analysis
    • 11.1. Global Market Share Analysis 2024
      • 11.2. Company Profiles
        • 11.2.1 Abbott
          • 11.2.1.1. Overview
          • 11.2.1.2. Products
          • 11.2.1.3. SWOT Analysis
          • 11.2.1.4. Recent Developments
          • 11.2.1.5. Financials (Based on Availability)
        • 11.2.2 Bharat Biotech International Limited
          • 11.2.2.1. Overview
          • 11.2.2.2. Products
          • 11.2.2.3. SWOT Analysis
          • 11.2.2.4. Recent Developments
          • 11.2.2.5. Financials (Based on Availability)
        • 11.2.3 Boehringer Ingelheim International GmbH
          • 11.2.3.1. Overview
          • 11.2.3.2. Products
          • 11.2.3.3. SWOT Analysis
          • 11.2.3.4. Recent Developments
          • 11.2.3.5. Financials (Based on Availability)
        • 11.2.4 GlaxoSmithKline plc.
          • 11.2.4.1. Overview
          • 11.2.4.2. Products
          • 11.2.4.3. SWOT Analysis
          • 11.2.4.4. Recent Developments
          • 11.2.4.5. Financials (Based on Availability)
        • 11.2.5 Haffkine Biopharmaceutical Corporation Limited
          • 11.2.5.1. Overview
          • 11.2.5.2. Products
          • 11.2.5.3. SWOT Analysis
          • 11.2.5.4. Recent Developments
          • 11.2.5.5. Financials (Based on Availability)
        • 11.2.6 HBI
          • 11.2.6.1. Overview
          • 11.2.6.2. Products
          • 11.2.6.3. SWOT Analysis
          • 11.2.6.4. Recent Developments
          • 11.2.6.5. Financials (Based on Availability)
        • 11.2.7 Merck & Co.
          • 11.2.7.1. Overview
          • 11.2.7.2. Products
          • 11.2.7.3. SWOT Analysis
          • 11.2.7.4. Recent Developments
          • 11.2.7.5. Financials (Based on Availability)
        • 11.2.8 Novartis Pharmaceuticals Corporation
          • 11.2.8.1. Overview
          • 11.2.8.2. Products
          • 11.2.8.3. SWOT Analysis
          • 11.2.8.4. Recent Developments
          • 11.2.8.5. Financials (Based on Availability)
        • 11.2.9 Sanofi
          • 11.2.9.1. Overview
          • 11.2.9.2. Products
          • 11.2.9.3. SWOT Analysis
          • 11.2.9.4. Recent Developments
          • 11.2.9.5. Financials (Based on Availability)
        • 11.2.10 Serum Institute of India Ltd.
          • 11.2.10.1. Overview
          • 11.2.10.2. Products
          • 11.2.10.3. SWOT Analysis
          • 11.2.10.4. Recent Developments
          • 11.2.10.5. Financials (Based on Availability)
        • 11.2.11 Valneva SE
          • 11.2.11.1. Overview
          • 11.2.11.2. Products
          • 11.2.11.3. SWOT Analysis
          • 11.2.11.4. Recent Developments
          • 11.2.11.5. Financials (Based on Availability)
        • 11.2.12 Zydus Group
          • 11.2.12.1. Overview
          • 11.2.12.2. Products
          • 11.2.12.3. SWOT Analysis
          • 11.2.12.4. Recent Developments
          • 11.2.12.5. Financials (Based on Availability)
List of Figures
  1. Figure 1: Global Live Attenuated Vaccines Market Revenue Breakdown (Billion, %) by Region 2024 & 2032
  2. Figure 2: North America Live Attenuated Vaccines Market Revenue (Billion), by Vaccine Type 2024 & 2032
  3. Figure 3: North America Live Attenuated Vaccines Market Revenue Share (%), by Vaccine Type 2024 & 2032
  4. Figure 4: North America Live Attenuated Vaccines Market Revenue (Billion), by Development 2024 & 2032
  5. Figure 5: North America Live Attenuated Vaccines Market Revenue Share (%), by Development 2024 & 2032
  6. Figure 6: North America Live Attenuated Vaccines Market Revenue (Billion), by Mode of Administration 2024 & 2032
  7. Figure 7: North America Live Attenuated Vaccines Market Revenue Share (%), by Mode of Administration 2024 & 2032
  8. Figure 8: North America Live Attenuated Vaccines Market Revenue (Billion), by Age Group 2024 & 2032
  9. Figure 9: North America Live Attenuated Vaccines Market Revenue Share (%), by Age Group 2024 & 2032
  10. Figure 10: North America Live Attenuated Vaccines Market Revenue (Billion), by Indication 2024 & 2032
  11. Figure 11: North America Live Attenuated Vaccines Market Revenue Share (%), by Indication 2024 & 2032
  12. Figure 12: North America Live Attenuated Vaccines Market Revenue (Billion), by End-use 2024 & 2032
  13. Figure 13: North America Live Attenuated Vaccines Market Revenue Share (%), by End-use 2024 & 2032
  14. Figure 14: North America Live Attenuated Vaccines Market Revenue (Billion), by Country 2024 & 2032
  15. Figure 15: North America Live Attenuated Vaccines Market Revenue Share (%), by Country 2024 & 2032
  16. Figure 16: Europe Live Attenuated Vaccines Market Revenue (Billion), by Vaccine Type 2024 & 2032
  17. Figure 17: Europe Live Attenuated Vaccines Market Revenue Share (%), by Vaccine Type 2024 & 2032
  18. Figure 18: Europe Live Attenuated Vaccines Market Revenue (Billion), by Development 2024 & 2032
  19. Figure 19: Europe Live Attenuated Vaccines Market Revenue Share (%), by Development 2024 & 2032
  20. Figure 20: Europe Live Attenuated Vaccines Market Revenue (Billion), by Mode of Administration 2024 & 2032
  21. Figure 21: Europe Live Attenuated Vaccines Market Revenue Share (%), by Mode of Administration 2024 & 2032
  22. Figure 22: Europe Live Attenuated Vaccines Market Revenue (Billion), by Age Group 2024 & 2032
  23. Figure 23: Europe Live Attenuated Vaccines Market Revenue Share (%), by Age Group 2024 & 2032
  24. Figure 24: Europe Live Attenuated Vaccines Market Revenue (Billion), by Indication 2024 & 2032
  25. Figure 25: Europe Live Attenuated Vaccines Market Revenue Share (%), by Indication 2024 & 2032
  26. Figure 26: Europe Live Attenuated Vaccines Market Revenue (Billion), by End-use 2024 & 2032
  27. Figure 27: Europe Live Attenuated Vaccines Market Revenue Share (%), by End-use 2024 & 2032
  28. Figure 28: Europe Live Attenuated Vaccines Market Revenue (Billion), by Country 2024 & 2032
  29. Figure 29: Europe Live Attenuated Vaccines Market Revenue Share (%), by Country 2024 & 2032
  30. Figure 30: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Vaccine Type 2024 & 2032
  31. Figure 31: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Vaccine Type 2024 & 2032
  32. Figure 32: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Development 2024 & 2032
  33. Figure 33: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Development 2024 & 2032
  34. Figure 34: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Mode of Administration 2024 & 2032
  35. Figure 35: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Mode of Administration 2024 & 2032
  36. Figure 36: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Age Group 2024 & 2032
  37. Figure 37: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Age Group 2024 & 2032
  38. Figure 38: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Indication 2024 & 2032
  39. Figure 39: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Indication 2024 & 2032
  40. Figure 40: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by End-use 2024 & 2032
  41. Figure 41: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by End-use 2024 & 2032
  42. Figure 42: Asia Pacific Live Attenuated Vaccines Market Revenue (Billion), by Country 2024 & 2032
  43. Figure 43: Asia Pacific Live Attenuated Vaccines Market Revenue Share (%), by Country 2024 & 2032
  44. Figure 44: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Vaccine Type 2024 & 2032
  45. Figure 45: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Vaccine Type 2024 & 2032
  46. Figure 46: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Development 2024 & 2032
  47. Figure 47: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Development 2024 & 2032
  48. Figure 48: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Mode of Administration 2024 & 2032
  49. Figure 49: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Mode of Administration 2024 & 2032
  50. Figure 50: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Age Group 2024 & 2032
  51. Figure 51: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Age Group 2024 & 2032
  52. Figure 52: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Indication 2024 & 2032
  53. Figure 53: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Indication 2024 & 2032
  54. Figure 54: Latin America Live Attenuated Vaccines Market Revenue (Billion), by End-use 2024 & 2032
  55. Figure 55: Latin America Live Attenuated Vaccines Market Revenue Share (%), by End-use 2024 & 2032
  56. Figure 56: Latin America Live Attenuated Vaccines Market Revenue (Billion), by Country 2024 & 2032
  57. Figure 57: Latin America Live Attenuated Vaccines Market Revenue Share (%), by Country 2024 & 2032
  58. Figure 58: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Vaccine Type 2024 & 2032
  59. Figure 59: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Vaccine Type 2024 & 2032
  60. Figure 60: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Development 2024 & 2032
  61. Figure 61: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Development 2024 & 2032
  62. Figure 62: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Mode of Administration 2024 & 2032
  63. Figure 63: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Mode of Administration 2024 & 2032
  64. Figure 64: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Age Group 2024 & 2032
  65. Figure 65: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Age Group 2024 & 2032
  66. Figure 66: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Indication 2024 & 2032
  67. Figure 67: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Indication 2024 & 2032
  68. Figure 68: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by End-use 2024 & 2032
  69. Figure 69: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by End-use 2024 & 2032
  70. Figure 70: Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion), by Country 2024 & 2032
  71. Figure 71: Middle East and Africa Live Attenuated Vaccines Market Revenue Share (%), by Country 2024 & 2032
List of Tables
  1. Table 1: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Region 2019 & 2032
  2. Table 2: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  3. Table 3: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  4. Table 4: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  5. Table 5: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  6. Table 6: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  7. Table 7: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  8. Table 8: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Region 2019 & 2032
  9. Table 9: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  10. Table 10: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  11. Table 11: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  12. Table 12: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  13. Table 13: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  14. Table 14: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  15. Table 15: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Country 2019 & 2032
  16. Table 16: U.S. Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  17. Table 17: Canada Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  18. Table 18: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  19. Table 19: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  20. Table 20: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  21. Table 21: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  22. Table 22: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  23. Table 23: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  24. Table 24: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Country 2019 & 2032
  25. Table 25: Germany Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  26. Table 26: UK Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  27. Table 27: France Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  28. Table 28: Italy Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  29. Table 29: Spain Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  30. Table 30: Rest of Europe Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  31. Table 31: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  32. Table 32: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  33. Table 33: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  34. Table 34: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  35. Table 35: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  36. Table 36: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  37. Table 37: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Country 2019 & 2032
  38. Table 38: Japan Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  39. Table 39: China Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  40. Table 40: India Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  41. Table 41: Australia Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  42. Table 42: Rest of Asia Pacific Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  43. Table 43: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  44. Table 44: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  45. Table 45: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  46. Table 46: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  47. Table 47: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  48. Table 48: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  49. Table 49: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Country 2019 & 2032
  50. Table 50: Brazil Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  51. Table 51: Mexico Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  52. Table 52: Rest of Latin America Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  53. Table 53: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Vaccine Type 2019 & 2032
  54. Table 54: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Development 2019 & 2032
  55. Table 55: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Mode of Administration 2019 & 2032
  56. Table 56: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Age Group 2019 & 2032
  57. Table 57: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Indication 2019 & 2032
  58. Table 58: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by End-use 2019 & 2032
  59. Table 59: Global Live Attenuated Vaccines Market Revenue Billion Forecast, by Country 2019 & 2032
  60. Table 60: South Africa Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  61. Table 61: Saudi Arabia Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032
  62. Table 62: Rest of Middle East and Africa Live Attenuated Vaccines Market Revenue (Billion) Forecast, by Application 2019 & 2032

STEP 1 - Identification of Relevant Samples Size from Population Database

Step Chart
bar chart
method chart

STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

approach chart
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.

Note* : In applicable scenarios

STEP 3 - Data Sources

Primary Research

  • Web Analytics
  • Survey Reports
  • Research Institute
  • Latest Research Reports
  • Opinion Leaders

Secondary Research

  • Annual Reports
  • White Paper
  • Latest Press Release
  • Industry Association
  • Paid Database
  • Investor Presentations
approach chart

STEP 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.

Frequently Asked Questions

Get a Free Sample

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

Pricing

$4,850
Single User License:
  • Only one user can access this report at a time
  • Users are not allowed to take a print out of the report PDF
$5,350
Multi User License:
  • The report will be emailed to you in PDF format.
  • Allows 1-10 employees within your organisation to access the report.
$8,350
Corporate License:
  • Sharable and Printable among all employees of your organization
  • Excel Raw data with access to full quantitative & financial market insights
  • Customization at no additional cost within the scope of the report
  • Graphs and Charts can be used during presentation

Looking for a Custom Report?

We offer personalized report customization at no extra cost, including the option to purchase individual sections or country-specific reports. Plus, we provide special discounts for startups and universities. Get in touch with us today!

sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image
sponsor image

Tailored for you

  • In-depth Analysis Tailored to Specified Regions or Segments
  • Company Profiles Customized to User Preferences
  • Comprehensive Insights Focused on Specific Segments or Regions
  • Customized Evaluation of Competitive Landscape to Meet Your Needs
  • Tailored Customization to Address Other Specific Requirements
avatar

Director of Business Development

Sarah L

The insights provided in this report were spot-on and exactly what we needed to guide our strategic planning. The level of detail on industry trends and forecasts is unmatched. It saved us countless hours and gave us a significant advantage!"

Discover the Latest Market Insight Reports

Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.

shop image 1

About Market Insights Report

Market Insights Reports offers comprehensive market research reports and analysis, giving businesses important information about their clients, rivals, and sector to help them make well-informed decisions on operations, marketing, and business strategy. We offer a variety of services in addition to market research, data analysis, and strategy planning. In order to find opportunities and learn more about our competitors and the industry at large, we employ competitive analysis. To identify areas for development, we also evaluate our performance against that of our rivals. We can determine the places at which we can offer our clients the most value by performing value chain analysis.

Additionally, clients receive a thorough overview of their industry business environment. We can find trends that help us forecast future possibilities and threats by examining global macroeconomic dynamics and consumer behavior patterns. By analyzing their features and advantages, contrasting them with comparable items on the market, and evaluating both their quantitative and qualitative performance, we comprehensively evaluate our clients' products. This allows us to assist customers in determining how their goods compare to those of their rivals and in creating successful marketing plans. Our group has been successful in gaining a thorough grasp of our clients' requirements and offering them creative solutions. We currently provide services to more than 50 nations in Europe, the Middle East, Africa, Latin America, Asia Pacific, and North America. Because of our global reach, we have been able to establish trusting bonds with our partners and clients in various nations, improving customer service and forging a more cohesive worldwide presence.

+1 2315155523

sales@marketinsights.report

  • Home
  • About Us
  • Industries
    • Aerospace & Defense
    • Automotive
    • Semiconductors & Electronics
    • Agriculture
    • Chemicals & Materials
    • Construction
    • Consumer Goods and Services
    • Energy & Power
    • Food & Beverage
    • Healthcare
    • Media & Technology
    • Industrial Machinery
    • Packaging
    • Professional Services
    • Animal Health & Nutrition
  • Services
  • Contact
Main Logo
  • Home
  • About Us
  • Industries
    • Aerospace & Defense
    • Automotive
    • Semiconductors & Electronics
    • Agriculture
    • Chemicals & Materials
    • Construction
    • Consumer Goods and Services
    • Energy & Power
    • Food & Beverage
    • Healthcare
    • Media & Technology
    • Industrial Machinery
    • Packaging
    • Professional Services
    • Animal Health & Nutrition
  • Services
  • Contact
sales@marketinsights.report

Business Address

Head Office

Office no. A 5010, fifth floor, Solitaire Business Hub, Near Phoenix mall, Pune, Maharashtra 411014

Contact Information

Craig Francis

Business Development Head

+1 2315155523

sales@marketinsights.report

Extra Links

AboutContactsTestimonials
ServicesCareer

Subscribe

Get the latest updates and offers.

PackagingAutomotiveHealthcareAgricultureConstructionEnergy & PowerFood & BeverageMedia & TechnologyAerospace & DefenseIndustrial MachineryChemicals & MaterialsProfessional ServicesAnimal Health & NutritionConsumer Goods and ServicesSemiconductors & Electronics

© 2025 AMA Research. All rights reserved

Testimonials
Privacy Policy
Terms and Conditions
FAQ

Related Reports

See the similar reports

report thumbnailU.S. Clinical Nutrition Market

U.S. Clinical Nutrition Market Strategic Market Roadmap: Analysis and Forecasts 2025-2033

report thumbnailTelerehabilitation Market

Telerehabilitation Market Unlocking Growth Potential: Analysis and Forecasts 2025-2033

report thumbnailAbsorbable Nasal Implant Devices Market

Absorbable Nasal Implant Devices Market Soars to 581.6 Million, witnessing a CAGR of 7 during the forecast period 2025-2033

report thumbnailLive cell encapsulation Market

Live cell encapsulation Market Dynamics and Forecasts: 2025-2033 Strategic Insights

report thumbnailNasal Spray Market

Nasal Spray Market Strategic Roadmap: Analysis and Forecasts 2025-2033

report thumbnailGene Vector Market

Gene Vector Market Decade Long Trends, Analysis and Forecast 2025-2033

report thumbnailEndocrine Testing Market

Endocrine Testing Market 2025 Trends and Forecasts 2033: Analyzing Growth Opportunities

report thumbnailPulmonary Function Testing Systems Market

Pulmonary Function Testing Systems Market Report Probes the 2 billion Size, Share, Growth Report and Future Analysis by 2033

report thumbnailAutomated Immunoassay Analyzers Market

Automated Immunoassay Analyzers Market Growth Opportunities and Market Forecast 2025-2033: A Strategic Analysis

report thumbnailDental Digital X-ray Market

Dental Digital X-ray Market Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

report thumbnailPharmaceutical Gelatin Market

Pharmaceutical Gelatin Market 2025 to Grow at 5.6 CAGR with 1.1 billion Market Size: Analysis and Forecasts 2033

report thumbnailLung Cancer Treatment Market

Lung Cancer Treatment Market Unlocking Growth Potential: 2025-2033 Analysis and Forecasts

report thumbnailECG Stress Test Market

ECG Stress Test Market 2025 to Grow at 8.1 CAGR with 2.3 Billion Market Size: Analysis and Forecasts 2033

report thumbnailHealthcare Payer Services Market

Healthcare Payer Services Market Report 2025: Growth Driven by Government Incentives and Partnerships

report thumbnailNon-animal Alternative Testing Market

Non-animal Alternative Testing Market Unlocking Growth Potential: Analysis and Forecasts 2025-2033

report thumbnailDegenerative Disc Disease Treatment Market

Degenerative Disc Disease Treatment Market Charting Growth Trajectories 2025-2033: Strategic Insights and Forecasts

report thumbnailHealthcare Assistive Robot Market

Healthcare Assistive Robot Market 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

report thumbnailUrinary Retention Therapeutics Market

Urinary Retention Therapeutics Market 2025 Market Trends and 2033 Forecasts: Exploring Growth Potential

report thumbnailSurgical Rasps Market

Surgical Rasps Market Strategic Insights: Analysis 2025 and Forecasts 2033

report thumbnailCarrier Screening Market

Carrier Screening Market 2025 Market Trends and 2033 Forecasts: Exploring Growth Potential